Study finds Cook Medical’s Hemospray is 98% successful in treating GI bleeding

A new, multi-centre study on Cook Medical’s Hemospray Endoscopic Hemostat device has revealed that the use of Hemospray demonstrated a more than 98% successful hemostasis rate, while the 30-day rebleeding rate was 10%. The results, ‘Successful hemostasis of active lower GI bleeding using a hemostatic powder as monotherapy, combination therapy, or rescue therapy’, were published in the April 2019 edition of Gastrointestinal Endoscopy.

Gelesis’ novel hydrogel GS500 prototype potential treatment for chronic constipation

Gelesis has announced the presentation of data from a clinical study demonstrating that GS500 prototype (GS500/CSP01) provided a significant reduction in colonic transit time (CTT) in patients with chronic idiopathic constipation (CIC) relative to placebo. The data were presented at Digestive Disease Week 2019, held in San Diego, CA.

Looking forward to Dublin 2019: An interview with ESCP President, Per Nilsson

In a series of interviews, we will be previewing this year’s ACPGBI annual meeting in Dublin, 1-3 July. We talked to Dr Per Nilsson, Consultant Colorectal Surgeon and Senior Lecturer at Karolinska University Hospital, Sweden and current President of the European Society of Coloproctology, who discussed the benefits and current evidence for ‘Watch and wait’ and surgery for regrowth after neoadjuvant radiotherapy for rectal cancer.

Fitness may affect risk of colorectal cancer and survival likelihood after diagnosis

Adults who were the most fit had the lowest risk of developing colorectal and lung cancer, and among individuals who developed lung or colorectal cancer, those who had high fitness levels before their cancer diagnosis were less likely to die compared with those who had low fitness levels. The findings, ‘Cardiorespiratory Fitness and Incident Lung and Colon Cancer in Men and Women: Results from the Henry Ford Exercise Testing (FIT) Cancer Cohort’, were published in Cancer, a peer-reviewed journal of the American Cancer Society.

Screening for colorectal cancer at 45 would avert 11,100 deaths over five years

Starting routine colorectal cancer screening at age 45 rather than 50 would decrease US cancer deaths by as much as 11,100 over five years, according to a new study led by researchers at the Stanford University School of Medicine. The move would also decrease the number of cancer cases nationwide by up to 29,400 over that time period. However, screening a greater number of older and high-risk adults would avert nearly three times as many diagnoses and deaths at a lower cost, the study found.

Integrated stratifying method for improved prognosis for colorectal cancer patients

A method that integrates tumour buds, lymphocytic infiltration, and their spatial relationship could better stratify patients with stage 2 colorectal cancer (CRC) at high risk for disease-specific death compared with traditional methods of clinical staging, according to results ‘Automated Analysis of Lymphocytic Infiltration, Tumor Budding, and Their Spatial Relationship Improves Prognostic Accuracy in Colorectal Cancer’,  published in Cancer Immunology Research, a journal of the American Association for Cancer Research.